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A B S T R A C T
Mitochondrial biogenesis is a key feature of energy expenditure and organismal energy balance. Genetic deletion
of PARP1 or PARP2 was shown to induce mitochondrial biogenesis and energy expenditure. In line with that,
PARP inhibitors were shown to induce energy expenditure in skeletal muscle. We aimed to investigate whether
pharmacological inhibition of PARPs induces brown or beige adipocyte differentiation. SVF fraction of human
pericardial adipose tissue was isolated and human adipose-derived mesenchymal stem cells (hADMSCs) were
differentiated to white and beige adipocytes. A subset of hADMSCs were differentiated to white adipocytes in the
presence of Olaparib, a potent PARP inhibitor currently in clinical use, to induce browning. Olaparib induced
morphological changes (smaller lipid droplets) in white adipocytes that is a feature of brown/beige adipocytes.
Furthermore, Olaparib induced mitochondrial biogenesis in white adipocytes and enhanced UCP1 expression.
We showed that Olaparib treatment inhibited nuclear and cytosolic PAR formation, induced NAD+/NADH ratio
and consequently boosted SIRT1 and AMPK activity and the downstream transcriptional program leading to
increases in OXPHOS. Olaparib treatment did not induce the expression of beige adipocyte markers in white
adipocytes, suggesting the formation of brown or brown-like adipocytes.
PARP1, PARP2 and tankyrases are key players in the formation of white adipose tissue. Hereby, we show that
PARP inhibition induces the transdifferentiation of white adipocytes to brown-like adipocytes suggesting that
PARP activity could be a determinant of the differentiation of these adipocyte lineages.
1. Introduction
In light of the recent advances the white and brown dichotomy of
adipose tissue was revisited upon the discovery of beige adipocytes [1].
Apparently, adipose tissue is a versatile organ that can perform lipid
storage, energy expenditure and other biological roles contributing to
energy homeostasis to meet the needs of the organism [2,3]. There are
two types of adipocytes with considerable oxidative phosphorylation
(OXPHOS) capacity, brown and beige adipocytes that are responsible
for facilitating energy expenditure, while white adipocytes are pri-
marily lipid storing cells. Classical brown adipocytes are mitochondria-
rich multilocular cells in which active OXPHOS and ATP synthesis is
uncoupled. These cells are typically found in the interscapular region of
newborn humans and around major arteries later in life [4,5]. Un-
stimulated beige cells reside in white adipose tissue depots and have
similar morphology to white adipocytes [6]. Beige adipocytes can
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efficiently induce mitochondrial biogenesis in response to adrenergic
stimulus in a similar fashion and efficiency as classical brown adipo-
cytes [1,7] that seems protect against obesity and diabetes [8–10].
Poly(ADP-ribose) polymerases (PARPs) represent a 17-member
protein family [11,12]. Although, PARPs were originally described as
DNA repair proteins, recent investigations pointed out that these en-
zymes also have a significant impact on cellular and organismal me-
tabolism [13] and within that, in regulating mitochondrial metabolism
[14–17]. There are several molecular pathways through which PARPs
exert their effects on the mitochondria (for review see [14]). From the
perspective of the current study, two energy pathways have high re-
levance. PARPs are enzymes that cleave NAD+ to build long branched
poly(ADP-ribose) (PAR) chains on target proteins. The vast majority of
PARP activity can be attributed to PARP1 and PARP2 [18] and they
represent a heavy burden on cellular NAD+ levels [19,20]. PARP1 and
PARP2, therefore, compete with other NAD+-dependent enzymes, such
as Sirt1 and, hence, impact on mitochondrial physiology [19–21].
Pharmacological or genetic inhibition of PARP1 or PARP2 induces
SIRT1 activity through inducing cellular NAD+ levels that leads to
mitochondrial biogenesis through activating transcriptional programs
driven by peroxisome proliferator activated receptor associated co-
factor (PGC)-1α and FOXO1 [22,23]. PARP1 also has multifaceted in-
teractions with another key energy sensor, AMP-activated kinase
(AMPK) [24–27].
PARP-mediated changes to bioenergetics impacted on the (central)
nerve system, skeletal, cardiac and smooth muscle, the liver, en-
dothelial cells, cancers and the white and the brown adipose tissue
[13,15,26,28–35]. Consequently, a plethora of metabolic diseases are
associated with the PARP-mediated derailment of bioenergetics
[13,36]. Genetic deletion of PARP1 can induce heat generation and
cold tolerance in mice that is attributed to brown adipocytes [19].
Moreover, the above detailed PARP-mediated elements of the energy
homeostasis (e.g. AMPK, Sirt1) were shown to be key mediators of
white, brown and beige adipocyte development or function [37–39]. In
the current study we set out to assess whether PARP inhibition by
Olaparib, a pan-PARP inhibitor [40] can cause a transdifferentiation of
white adipocytes to beige or brown adipocytes.
2. Materials and methods
2.1. Chemicals
Chemicals were obtained from Sigma-Aldrich (St. Louis, MO, USA)
unless stated otherwise.
2.2. Ethical statement
The study protocol was approved by the Ethics Committee of the
University of Debrecen (Hungary) and the National Medical Research
Council Committee of Human Reproduction (ETT TUKEB). All experi-
ments were carried out in accordance with the Declaration of Helsinki
and the approved ethical guidelines and regulations. Written informed
consent from all participants was obtained before the surgical proce-
dure.
2.3. Isolation, culture and differentiation of hADMSCs
From human pericardial/mediastinal adipose tissue of patients un-
dergoing a planned cardiac surgery (e.g. valve surgery, coronary bypass
surgery, Batista operation) stromal vascular fraction (SVFs) was iso-
lated and from the SVF human adipose-derived mesenchymal stem cells
(hADMSCs) were cultivated. No exclusions were applied regarding BMI,
age, gender or medications of the patients.
On the day of heart surgery the mediastinal adipose tissue speci-
mens were processed as described in [41]. Samples were digested in
PBS with 120 U/ml collagenase for 1 h at 37 °C and filtered through a
sieve with a pore size of 100 μm. Isolated hADMSCs were resuspended
in DMEM-F12 HAM medium containing 10% FBS and seeded to the
appropriate vessels. After cell culture reached confluency, differentia-
tion was initiated by using FBS free medium. White adipogenic differ-
entiation was carried out using the protocol described by Fischer-Po-
sovszky and co-workers [42]. To induce beige adipogenic
differentiation cells were treated according to Elabd and co-workers
[43]. To assess the result of PARP inhibition, white adipocytes were
differentiated in the presence of 1 μM Olaparib (Selleckchem, Munich,
Germany). This concentration was determined by testing our cell model
(hADMSCs) with Olaparib for toxicity in a range of 100 nM–4 µM for
toxicity. Cells were assayed after 14 days after the induction of differ-
entiation.
2.4. Microscopic analysis of differentiated hADMSC
After 2-weeks of differentiation microscopic images were acquired
with an OPTIKA XDS-3 trinocular inverted microscope (Science
Services, Munich, Germany) using IOS LWD 20X/0.40 Ph (w.d.
7.66mm) objective at 25 °C and images were processed using SharpCap
2.8 software.
2.5. Confocal microscopy
hADMSCs were seeded on glass coverslips and differentiated as
described in 2.3. For the visualization of lipid droplets, on the last day
of the differentiation cells were fixed with 4% formaldehyde for 20min
at 37 °C then rinsed three times with 1× PBS. Following the fixation
cells were stained for 20min at room temperature with Nile Red dye
diluted in 1x PBS in concentration of 10 µg/ml. Cells were washed once
with PBS and once with water.
On the last day of the differentiation the other set of cells were
stained with Mitotracker Red (Thermo Scientific, MA, USA) to assess
the mitochondrial network using a working concentration of 100 nM for
30min at 37 °C. Cells were washed once with PBS and cells were fixed
with 4% formaldehyde for 20min at 37 °C then rinsed three times with
1× PBS.
The nuclei were stained with DAPI special formation (NucBlue®
Fixed cell Stain ReadyProbes™ reagent, Life Technologies, Carlesbad,
CA, USA) and rinsed in 1× PBS again.
Confocal images were acquired with a Leica TCS SP8 confocal mi-
croscope (Leica Microsystems, Wetzlar, Germany) using an HC PL APO
CS2 63×/1.40 OIL immersion objective on a DMI6000 CS microscope
at 25 °C. The following lasers were applied: OPSL 488 for Mitotracker
Red and for Nile Red, and 405 visible for DAPI. Images were processed
using LAS X 2.0.1.14392 software. The number of mitochondria was
determined using CellProfiler software (The Broad Institute of MIT,
MA).
2.6. Gene expression and RT-qPCR
Reverse transcription-coupled real time quantitative PCR (RT-qPCR)
reactions were performed similarly as in [44]. Briefly, total RNA was
prepared using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) ac-
cording to the manufacturer's instructions, then reverse transcription
was performed (High Capacity cDNA Reverse Transcription Kit, Applied
Biosystems, Foster City, CA, USA). 10× diluted cDNA was used for RT-
qPCR reactions (PCRBIOSYSTEMS, qPCRBIO SyGreen Mix Lo-ROX,
London, United Kingdom). The RT-qPCR reactions were performed
using the Light-Cycler system (Roche Applied Science, Mannheim,
Germany). Primers are summarized in Table 1. Expression was nor-
malized to the geometric mean of three control genes (cyclophyllin, β-
actin, 36B4 or YWAHZ).
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2.7. Protein extraction and Western blotting
The isolation of cytoplasmic and nuclear fraction of proteins from
hADMSCs and the subsequent Western blotting are described in [45].
Blots were probed with the antibodies summarized in Table 2.
Signals were detected using enhanced chemiluminescence (ECL)
and were captured by ChemiDoc Touch (Bio-Rad Laboratories, CA,
USA).
2.8. Determination of NAD+/NADH ratio
NAD/NADH Quantification Kit (Sigma) was used for the determi-
nation of NAD+/NADH ratio following the manufacturer's instructions.
NAD+ and NADH content was normalized for protein content.
2.9. Determination of the size and number of lipid droplets
Preadipocytes were seeded and differentiated on PerkinElmer 96-
well black clear bottom plate. On the last day of the differentiation cells
were fixed with 4% formaldehyde for 20min at 37 °C then rinsed two
times with 1× PBS. Following the fixation cells were stained with Nile
Red dye using a working concentration of 10 µg/ml and diluted in 1×
PBS for 20min at room temperature (diluted from 10mg/ml stock so-
lution). The dye charges the lipid droplets enabling the visualization of
the pattern and size of lipid droplets in adipocytes. Cells were washed
once with PBS and once with water. The nuclei were stained with DAPI
special formation (NucBlue® Fixed cell Stain ReadyProbes™ reagent,
Life Technologies, Carlesbad, CA, USA) and rinsed in 1× PBS again.
Images were acquired with an Opera Phenix™ High-Content Screening
System (PerkinElmer, Waltham, MA, USA) 40× water immersion
objective at 25 °C. 488 nm laser was used for the detection of Nile Red
and 405 nm laser for DAPI. Images were processed using Harmony
software and analyzed by Image J software [46]. We calculated the
ratio of differentiation by counting the cells containing at least two
large lipid droplets (differentiated) and those that did not (un-
differentiated).
2.10. Determination of oxygen consumption (OCR)
Oxygen consumption rate was determined using XF96 Flux Analyzer
(Agilent Technologies, CA, USA). hADMSCs were seeded in 96-well
assay plates, then differentiated as described previously. After re-
cording the baseline oxygen consumption, cells received a single bolus
dose of dibutyril-cAMP (500 μM final concentration) simulating adre-
nergic stimulation. Then OCR was recorded every 5min for 30min. As
a last step, cells received a single bolus dose of antimycin A (10 μM) and
rotenone (2.5 μM) for distinguishing the mitochondrial from non-mi-
tochondrial oxygen consumption. After the measurement cells were
fixed and Sulphorhodamine B assay was used for the determination of
total protein content. OCR values were normalized to protein content
and normalized readings were analyzed and plotted.
2.11. Immunoprecipitation
Cells were lysed in RIPA lysis buffer (50mM Tris, 150mM NaCl,
0.1% SDS, 1% Triton X 100, 0.5% sodium deoxycolate, 1 mM EDTA,
1mM Na3VO4, 1mM NaF and protease inhibitor cocktail). FOXO1
acetylation levels were analyzed by immunoprecipitation from lysates
with anti-FOXO1 (1:1000, Cell Signalling, Danvers, MA, USA) followed
by Western blot using an acetyl-lysine antibody (1:500, Cell Signalling)
that was normalized to total FOXO1 levels.
2.12. Statistical analysis
Throughout the text n refers to the number of donors (biological
replicates) assessed. All data is represented as average ± SEM, unless
stated otherwise. Data were analyzed by using GraphPad Prism 3
software and statistical analysis was performed by using one-way
ANOVA followed by Dunnett’s post-hoc test.
3. Results
3.1. Olaparib induces mitochondrial biogenesis in white adipocytes
In the study we used white adipose tissue-derived stem cells
(hADMSCs) that were differentiated into white or beige adipocytes; a
subset of the progenitor cells that differentiated into white adipocytes
received OLA, a potent PARP inhibitor that is used in the clinical
practice. First, we assessed the morphology of the cells, as in previous
studies smaller lipid droplets were characteristic for beige differentia-
tion [47–49]. Beige adipocytes and OLA-treated white adipocytes had
Table 1
Primers used in RT-qPCR reactions.
Gene Forward primer Reverse primer
36B4 Human 5′-CCATTGAAATCCTGAGTGATGTG-3′ 5′-GTCGAACACCTGCTGGATGAC-3′
β-actin Human 5′-GACCCAGATCATGTTTGAGACC-3′ 5′-CATCACGATGCCAGTGGTAC-3′
Cyclophilin A Human 5′-GTCTCCTTTGAGCTGTTTGCAGAC-3′ 5′-CTTGCCACCAGTGCCATTATG-3′
PGC1α Human 5′-TTCCTCTGACCCCAGAGTCACC-3′ 5′-TTGCAAGAGGACTTCAGCTTTGG-3′
PPARγ Human 5′-GTGGCCGCAGATTTGAAAGAAG-3′ 5′-CCATGGTCATTTCGTTAAAGGCTG-3′
PRDM16 Human 5′-CACTGTGCAGGCAGGCTAAGAA-3′ 5′-AGAGGTGGTTGATGGGGTGAAA-3′
TBX1 Human 5′-TCCCACCTTCCAAGTGAAGCTC-3′ 5′-CACGATTTGCTTCATCCACTGC-3′
TMEM26 Human 5′-ACCTCCCATGTGTGGACATCCT-3′ 5′-ACCAACAGCACCAACAACCTCA-3′
SIRT1 Human 5′-TGGCAAAGGAGCAGATTAGTAGGC-3′ 5′-TGGACTCTGGCATGTCCCACT-3′
UCP1 Human 5′-AACGAAGGACCAACGGCTTTC-3′ 5′-GGCACAGTCCATAGTCTGCCTTG-3′
YWAHZ Human 5′-CCGCCAGGACAAACCAGTAT-3′ 5′-ACTTTTGGTACATTGTGGCTTCAA-3′
Table 2
List of antibodies used in the study.
Primary antibodies
β-Actin−Peroxidase (Sigma Aldrich) mouse polyclonal 1:25000
ACC (C83B10) (Cell Signaling) rabbit monoclonal 1:1000
Phospho-ACC(Serine79) (Cell Signaling) rabbit polyclonal 1:1000
AMPKα (D63G4) (Cell signaling) rabbit monoclonal 1:1000
Phospho- AMPKα (Threonine172) (40H9) (Cell
signaling)
rabbit monoclonal 1:1000
FOXO1 (C29H4) (Cell Signaling) rabbit monoclonal 1:1000
Histone H3 (Cell Signaling) rabbit polyclonal 1:1000
LaminB1 (Cell signaling) rabbit monoclonal 1:1000
PGC1α (Thermo Fisher Scientific) rabbit polyclonal 1:1000
Poly(ADP-ribose) (PAR) (Enzo Life Science) mouse monoclonal 1:500
TBX1 (Gene Tex) rabbit polyclonal 1:500
UCP1 (Sigma Aldrich) mouse monoclonal 1:1000
Secondary antibodies
HRP-linked anti-rabbit IgG (Cell Signaling) goat polyclonal 1:2000
Peroxidase conjugated anti-mouse IgG (Sigma
Aldrich)
rabbit polyclonal 1:80000
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Fig. 1. Olaparib treatment brings about morphological changes in white adipocytes that renders them similar to brown adipocytes. Human adipose-derived me-
senchymal stem cells (hADMSCs) were differentiated to white adipocytes, beige adipocytes and white adipocytes treated with Olaparib (OLA) (n= 3/3/3).
Differentiated cells were photographed (A) using phase-contrast microscope (B) and after Nile Red (red) and DAPI staining (blue) using a confocal microscope.
Contrast and brightness were adjusted to pictures represented only DAPI staining. In the same cells the (C) count and (D) the size of the lipid droplets was measured
using Image J software. (E) The ratio of differentiated (cells with more than 2 large lipid droplet) and undifferentiated adipocytes was calculated. * indicate
statistically significant difference between the group of white adipocytes and the any of the other two groups as indicated, at p < 0.05. On the graphs
average ± SEM was plotted.
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Fig. 2. Olaparib treatment induces browning in white adipocytes. Human adipose-derived mesenchymal stem cells (hADMSCs) were differentiated to white adi-
pocytes, beige adipocytes and white adipocytes treated with Olaparib (OLA). (A) Differentiated cells were charged with Mitotracker Red (in red) and the nuclei were
visualized by DAPI (in blue). (B) These confocal pictures were further analyzed by using CellProfiler and the number of mitochondria was determined. (C) Basal and
cAMP-induced cellular oxygen consumption rate (OCR) were determined by Seahorse extracellular flux analyzer (n= 3). (D) UCP1 mRNA levels (n=5) by RT-qPCR
and protein levels in cytoplasmic fraction by western blotting (n= 5) were determined. A representative blot is shown. * and ** indicate statistically significant
difference between the group of white adipocytes and the any of the other two groups as indicated, at p < 0.05 or p < 0.01, respectively. On the graphs
average ± SEM was plotted.
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smaller lipid droplets as compared to white adipocytes (Fig. 1A–D). We
assessed the rate of differentiation, too. Beige differentiation and OLA
treatment decreased the rate of differentiation as compared to white
adipocytes (Fig. 1E).
Next, we assessed mitochondrial content using Mitotracker red
staining. Beige adipocytes had markedly higher mitochondrial content
than white adipocytes (Fig. 2A, B). OLA treatment also significantly
induced mitochondrial content in white adipocytes (Fig. 2A, B). In-
creases in mitochondrial content was translated into increased mi-
tochondrial oxygen consumption rates (OCR) in beige adipocytes and in
OLA-treated white adipocytes when induced by a membrane-permeable
cAMP analogue (500 µM dibutyril-cAMP), mimicking adrenergic sti-
mulus (Fig. 2C). Finally, we assessed the expression of uncoupling
protein-1 (UCP1), the major molecular marker of brown and beige
adipocytes which is responsible for mitochondrial uncoupling. UCP1
mRNA and protein expression was induced in beige adipocytes and
OLA-treated white adipocytes as compared to white adipocytes
(Fig. 2D).
Taken together, OLA, similarly to the previous observations
[19–21,50,51], induces mitochondrial biogenesis and probably un-
coupling in our cellular model.
3.2. Olaparib treatment induces Sirt1 and AMPK
We assessed the molecular pathways that can be responsible for the
induction of mitochondrial biogenesis. Sirt1 activation had been linked
to PARP inhibition by numerous prior studies [19,21,50–53] and Sirt1
activation was shown to play a major role in beige and brown differ-
entiation [54–56]. OLA inhibited PARP activity in the nuclear and cy-
tosolic fractions (Fig. 3A). Interestingly, beige differentiation decreased
cytosolic PAR formation (Fig. 3A). Decreased PARP activity slightly
increased NAD+ levels, significantly reduced NADH levels that culmi-
nated in an increased NAD+/NADH ratio in beige adipocytes and OLA-
treated white adipocytes (Fig. 3B) that is a known activator of SIRT1
[57]. We next assessed the expression of Sirt1 and its downstream
targets. Interestingly, in beige adipocytes we observed decreased the
expression of SIRT1 (Fig. 3C) and FOXO1 (Fig. 3D), while PGC1α
protein expression was drastically induced (Fig. 3F) when compared to
white adipocytes. OLA treatment did not change the expression of
SIRT1, FOXO1, in turn, PGC1α expression was induced as compared to
the white adipocyte control (Fig. 3C-D, F). Importantly, OLA treatment
decreased the acetylation of FOXO1 suggesting increased SIRT1 activity
(Fig. 3F).
Another pathway that can induce mitochondrial biogenesis is
AMPK. We assessed AMPK activity through assessing key phosphor-
ylation events. AMPK is a trimeric enzyme that is phosphorylated upon
activation at Threonine172 of the α subunit [58], AMPK phosphoryla-
tion levels at α Threonine172 were higher in beige cells as compared to
white adipocytes (Fig. 4A). Acetyl-CoA carboxylase (ACC) is phos-
phorylated by AMPK at Serine79 and is, therefore, considered a suitable
marker of AMPK activation. ACC phosphorylation were induced dras-
tically in beige as compared to white adipocytes (Fig. 4B). AMPK
phosphorylation was induced upon OLA treatment in white adipocytes
to similar levels as in beige adipocytes (Fig. 4A) and we observed trend
for higher pACC levels, too (Fig. 4B).
3.3. PARP inhibition yields brown-like adipocytes
Finally, we assessed markers of beige adipocyte differentiation,
PRDM16, TMEM26, PPARγ1 and TBX1 [1,59,60]. The expression of all
markers were higher in beige adipocytes than in white adipocytes
(Fig. 5). Nevertheless, the expression of these markers was not induced
in OLA-treated white adipocytes as compared to control white adipo-
cytes (Fig. 5).
4. Discussion
In this study we provided evidence that Olaparib (OLA), induces
mitochondrial biogenesis and, hence, browning in human white adi-
pocytes. OLA is a pan-PARP inhibitor, inhibiting all members of the
PARP family [40]. PARP1 [15,19,20,27,28,50,51,61–63], PARP2
[20,21,31], PARP7 [64], PARP10 [34], tankyrases [65] are all im-
plicated in regulating mitochondrial metabolism. The vast majority of
PARP activity is attributed to PARP1 and PARP2 [18,31,66] making it
likely that PARP1 and PARP2 are responsible for mitochondrial bio-
genesis upon OLA treatment. Nevertheless, the drastic inhibition of
PARP activity in the cytoplasm suggest the involvement of other, yet
uncovered, PAR(P)-dependent pathways in OLA-elicited effects. It is of
note that studies using other, structurally different PARP inhibitors are
necessary to validate our observations in the context of beige/brown
differentiation, however, in different model systems other pharmaco-
logical PARP inhibitors and genetic PARP inhibition was shown to in-
duce mitochondrial biogenesis [15,19,20,27,28,50,51,61–63].
The involvement of PARPs in mitochondrial physiology was first
shown in 1998 by Virág et al. [17], since then a plethora of pathways
converging on mitochondrial metabolism were shown to be PARP-de-
pendent (reviewed in [14]). In this study we found the upregulation of
two pathways by OLA, namely, the induction of SIRT1 and AMPK.
Pharmacological PARP inhibition was shown to increase NAD+ le-
vels and hence induce SIRT1 that subsequently drives mitochondrial
biogenesis in skeletal muscle [19,50]. Our study extends these ob-
servations by showing that brown adipose tissue is also a subject of
induction of mitochondrial biogenesis by PARP inhibition. While pre-
vious studies showed the upregulation of SIRT1 activity in beige dif-
ferentiation [37–39,56,67], in our model (SVF from pericardial adipose
tissue), in beige adipocytes we found a downregulation of the expres-
sion of SIRT1 and FOXO1, nevertheless, SIRT1 activity was induced.
These changes are puzzling in light of the previous literature, never-
theless, can be an intrinsic feature of the pericardial adipose tissue,
indeed, the metabolic behavior of the adipose tissue from different
anatomical locations is known [68–70] and mediastinal/pericardial
adipose tissue stem cells exhibit beige characteristics [71] that may
explain discrepancies between other studies [38,39,48,72,73]. None-
theless, OLA treatment readily induced SIRT1 activity and its down-
stream targets enabling efficient induction of mitochondrial biogenesis.
AMPK activation was very pronounced in beige and OLA-treated
white adipocytes as compared to untreated white adipocytes. AMPK
was shown to be key player in driving brown adipose tissue and beige
adipocyte differentiation and function [38,39,72–74]. AMPK is an up-
stream regulator of SIRT1 [75] suggesting close collaboration between
the two pathways. AMPK and PARP1 has an intricate and multifaceted
interactions [14,24–27].
When we assessed the differentiation markers, PRDM16, PPARγ1
and TBX1 did not show major increase in OLA-treated white adipocytes
as compared to beige adipocytes. Nevertheless, OLA-treatment induced
browning, characterized by mitochondrial biogenesis and increases in
UCP1 expression, features of brown and beige adipocytes. These data
make it likely that OLA rather induces the differentiation of brown or
brown-like adipocytes than true beige cells. The other explanation
could be, as mentioned earlier, that mediastinal/pericardial adipose
tissue stem cells inherently exhibit beige characteristics [71], therefore,
beige characteristics cannot be further induced in these cells.
In this study we show that inhibition PARP enzyme activity induces
browning in white adipocytes. A large set of previous studies have
shown that PARP1 and PARP2 are necessary for efficient white adipo-
cyte differentiation [35,65,76–80]. In good agreement with that, OLA
treatment and beige differentiation decreased the rate of differentia-
tion. It is tempting to speculate that PARP activation could be vital for
making the decision on the course of adipocyte differentiation between
the white and brown/beige lineages. Along the same logic, as high fat
feeding can induce PARP activity [19], in obesity or in insulin
L. Nagy, et al. Biochemical Pharmacology 167 (2019) 76–85
81
resistance PARP activation may hamper brown or beige adipocytes
deregulating organismal energy balance and, hence, may play patho-
physiological role in these diseases.
Data availability
All primary data is uploaded to https://figshare.com/s/
78810e13d8ad50b1b58d (DOI: 10.6084/m9.figshare.7868417)
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